

LEQVIO® – HARNESSING THE NATURAL PROCESS OF RNAi TO LOWER LDL-C IN ADULT PATIENTS WITH HYPERCHOLESTEROLEMIA



RNA interference (RNAi) is a biological process that regulates gene expression by inhibiting translation of specifically targeted messenger RNA (mRNA) into proteins.¹

Therapies called small interfering RNAs (siRNAs) have been developed to harness the body's natural process of RNAi.³




LEQVIO is a first-in-class siRNA therapy that lowers low-density lipoprotein cholesterol (LDL-C) using similar cellular components as RNAi.²

It consists of a guide strand and a passenger strand. The passenger strand is attached to a molecule called GalNAc.²

The efficacy and safety of LEQVIO have been studied in 3 Phase 3 clinical trials in adults with elevated LDL-C despite maximally tolerated statin therapy with or without ezetimibe. ORION-9 examined adults with heterozygous familial hypercholesterolemia (HeFH). ORION-10 examined adults with atherosclerotic cardiovascular disease (ASCVD), and ORION-11 examined adults with ASCVD or at an increased risk of ASCVD.^{2*}

LEQVIO WORKS DIFFERENTLY THAN OTHER LDL-C-LOWERING TREATMENTS AS A COMPLEMENT TO DIET AND EXERCISE²



TARGETED DELIVERY TO HEPATOCYTES²



SLOW RELEASE INTO THE CYTOPLASM³



CATALYTIC ACTIVITY OF LEQVIO-BOUND RISC DEGRADES MULTIPLE COPIES OF TARGET mRNA THEREBY PROLONGING ACTIVITY⁴

*Factors that increase risk of cardiovascular disease include heterozygous familial hypercholesterolemia, type 2 diabetes mellitus, or 10-year risk of $\geq 20\%$.¹

INDICATION

LEQVIO (inclisiran) injection is indicated as an adjunct to diet and exercise to reduce low-density lipoprotein cholesterol (LDL-C) in adults with hypercholesterolemia, including heterozygous familial hypercholesterolemia (HeFH).

IMPORTANT SAFETY INFORMATION

Contraindication: LEQVIO is contraindicated in patients with a prior serious hypersensitivity reaction to inclisiran or any of the excipients in LEQVIO. Serious hypersensitivity reactions have included anaphylaxis and angioedema.

Hypersensitivity Reactions: Hypersensitivity reactions, including anaphylaxis and angioedema, have been reported in patients treated with LEQVIO. Advise patients on the signs and symptoms of hypersensitivity reactions and instruct patients to seek medical attention promptly.

Adverse Reactions: Adverse reactions in clinical trials ($\geq 3\%$ of adult patients treated with LEQVIO and more frequently than placebo) were injection site reaction, arthralgia, and bronchitis.

Please [click here](#) for LEQVIO full Prescribing Information.

1. Ray KK et al. *N Engl J Med.* 2020;382(16):1507-1519. 2. Leqvio. Prescribing information. Novartis Pharmaceuticals Corp. 3. Khvorova A. *N Engl J Med.* 2017;376(1):4-7. 4. Fitzgerald K et al. *N Engl J Med.* 2017;376(1):41-51.

